PIK3CA and breast neoplasm: These analyses resulted in the identification of 62 different phosphosites in PIK3CA mutated breast tumors, including RPS6KA5 and EIF2AK4, explaining the activation of the pathway and revealing possible druggable kinases in this pathway [5].